)
SEE THE SCAN FROM A REAL DUPIXENT PATIENT
to see results
CT scan of patient from clinical trial. Individual results may vary.
Week 24
(key secondary
endpoint)2
27%SignificantIMPROVEMENT
with DUPIXENT
with placebo
(P<0.0001)2,b
Week 52
(other secondary
endpoint)2
38%ContinuedIMPROVEMENT
with DUPIXENTc
with placebo2,d
Analysis was not multiplicity controlled.
Results are descriptive.2
b Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -5.13 (95% CI: -5.80, -4.46)
(-5.21 from a baseline score of 18.12 vs -0.09 from a baseline score of 17.65, respectively) (P<0.0001).2
c Nominal improvement observed at Week 52 in LMK-CT score.2
d Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -6.94 (95% CI: -7.87, -6.01) (-6.83 from a
baseline score of 18.42 vs 0.11 from a baseline score of 17.65, respectively).2
DUPIXENT DEMONSTRATED SUBSTANTIAL REDUCTIONS IN
OPACIFICATION ACROSS ALL INDIVIDUAL SINUSES AT WEEK 242
Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.1
INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies
of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.1
Explore the Safety Data and Study Designs
Dosage and
Administration
See the recommended dosing and administration options for patients on DUPIXENT.